RO7837195

DRUG2 trials

Sponsors

Genentech Inc., Genentech, Inc.

Conditions

Moderately to Severely Active Ulcerative Colitis (UC)Ulcerative Colitis

Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

RecruitingNCT06979336

Genentech, Inc.Ulcerative Colitis

Start: 2025-09-29End: 2028-10-31Target: 224Updated: 2026-08-27

A Phase IIb, Multicenter, Double-Blind, Placebo-Controlled Induction Study with an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients with Moderately to Severely Active Ulcerative Colitis

RecruitingCTIS2025-520690-39-00

Genentech Inc.Moderately to Severely Active Ulcerative Colitis (UC)

Start: 2025-11-04Target: 84Updated: 2025-10-08